Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing institution founded as the New York Cancer Hospital in 1884 and now located in the upper east side of New York City, adjacent to the health sciences campuses of Cornell University Medical College and Rockefeller University. The Center's mission is the progressive control and cure of cancer through programs of research, patient care, and education. MSKCC is dedicated to the study of cancer through a defined spectrum of laboratory research, an interactive program spanning basic and clinical science, a strong capability for basic-to-clinic technology transfer, a structured program of clinical cancer research, state-of-the art clinical programs, including in-patient and out-patient clinical care, community care focused on early diagnosis and specific cancers and a strategically selected set of priorities in population-based research that addresses issues of both local and national importance. The research activities of MSKCC are administratively organized in seven research programs: Molecular Biology, Cell Biology, Cellular Biochemistry and Biophysics, Immunology, Molecular Pharmacology and Therapeutics, Clinical Research and Cancer Prevention and Control. These Programs are supported by 13 CCSG-supported Core Facilities as well as others supported entirely by institutional resources. The Core Facilities for which CCSG support is requested are: General Animal, Animal Health, Transgenic Mouse, Glassware Washing, Media Preparation, Flow Cytometry, Microchemistry, Molecular Cytology, Analytical Pharmacology, Human Tissue Procurement, Research Pharmacy Support, Biostatistics, and Clinical Research Support. Funds are also requested for Clinical Protocol Scientific Review and Monitoring and for Development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-33
Application #
2447991
Study Section
Subcommittee G - Education (NCI)
Program Officer
Bhorjee, Jaswant
Project Start
1977-01-01
Project End
2002-12-31
Budget Start
1998-03-02
Budget End
1998-12-31
Support Year
33
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Jakub, James W; Peled, Anne Warren; Gray, Richard J et al. (2018) Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surg 153:123-129
Ulaner, Gary A; Lyashchenko, Serge K; Riedl, Christopher et al. (2018) First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. J Nucl Med 59:900-906
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
McFarland, Daniel C; Shaffer, Kelly M; Tiersten, Amy et al. (2018) Physical Symptom Burden and Its Association With Distress, Anxiety, and Depression in Breast Cancer. Psychosomatics 59:464-471
Aherne, Emily A; Plodkowski, Andrew J; Montecalvo, Joseph et al. (2018) What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology? Lung Cancer 118:83-89
Perrin, Thomas; Midya, Abhishek; Yamashita, Rikiya et al. (2018) Short-term reproducibility of radiomic features in liver parenchyma and liver malignancies on contrast-enhanced CT imaging. Abdom Radiol (NY) 43:3271-3278
Apte, Aditya P; Iyer, Aditi; Crispin-Ortuzar, Mireia et al. (2018) Technical Note: Extension of CERR for computational radiomics: A comprehensive MATLAB platform for reproducible radiomics research. Med Phys :
Santini, Fernando C; Rizvi, Hira; Plodkowski, Andrew J et al. (2018) Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res 6:1093-1099
Ma, Jennifer; Setton, Jeremy; Lee, Nancy Y et al. (2018) The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nat Commun 9:3292

Showing the most recent 10 out of 8799 publications